Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL
2024-519587-40-00Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of LY3884961 in Parkinson's disease (GBA-PD), sponsored by Eli Lilly and Company. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events, Incidence of procedure- or treatment-emergent safety findings and 1 more. Planned start Jun 2025; status: withdrawn.
02
Drugs
LY3884961
03
Conditions
Parkinson's disease (GBA-PD)
Beyond the preview
Go deeper on 2024-519587-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519587-40-00.